Rapid infectious disease test Xpert® Carba-R

for carbapenemase-producing enterobacteriaceaebacteriamolecular

The emergence and global spread of carbapenemase producing Enterobacterales (CPE) is of great concern to health services worldwide1 Carbapenem resistance results in increased mortality in hospitalized patients and is associated with higher total hospital costs2 CPE are multi-drug resistant organisms that can cause serious infections and require interventions in healthcare settings to prevent spread3 ECDC and CDC recommend comprehensive infection control measures for patients who are colonized or infected with carbapenemase-producing organisms3,4 The Solution Detection and differentiation of patients with the Xpert Carba-R test can quickly alert clinicians and infection preventionists to the presence of gene sequences associated with carbapenem non-susceptibility apid detection and differentiation of the IMP, NDM, or VIM metallo-beta-lactamase gene sequences from pure colonies helps clinicians optimize patient management and direct therapeutic strategy Rectal and perirectal swabs assist with infection control measures* On-demand identification of the most prevalent carbapenemase gene families enables healthcare systems to prevent onward transmission throughout the patient pathway and facilitates more efficient bed management for improved hospital flow5 The Impact Reduced turnaround time enables rapid infection control measure to reduce transmission6,7 Minimize the number of bed-days lost due to CPE compared to culture5 Decrease in CPE colonization and infection rates with fast PCR results8